PSMD1 and Huntington disease: The adenoviral vector vaccine ChAdOx1 elicited lower humoral response with lower GMTs for anti-S1 and anti-RBD antibodies than the mRNA-1273 vaccine in both HD patients (anti-S1: 2.74 vs. 5.26 EU/mL, p = 0.001; anti-RBD: 2.43 vs. 2.64 EU/mL, p < 0.001) and healthy controls (anti-S1: 5.46 vs. 19.57 EU/mL, p < 0.001; anti-RBD: 4.27 vs. 12.97 EU/mL, p < 0.001; Figure 4a,b).